Madrigal Pharmaceuticals, Inc. MDGL Unrecognized compensation cost related to non-vested awards

Unrecognized compensation cost related to non-vested awards at other companies

Digital RealtyDLR

$26.4M+53.0%

EFC

Ellington Financial Inc.EFC

$910.5K+24.0%

Hyatt HotelsH

$9M+28.6%

McCormick & Company, IncorporatedMKC

$11.55M-2.5%

EMCOR GroupEME

$5.15M+3.1%

Starwood Property TrustSTWD

$13.99M+4.8%

Other financials

Income statement

See full

Revenue$311.3M+127%

Gross profit$43.5M—

Operating income-$92.7M-16.9%

Net income-$94.4M-28.9%

EPS (diluted)-$3.25-24.5%

Balance sheet

See full

Cash & equivalents$232.2M+23.1%

Total debt$377.3M+187%

Total equity$543.5M-23.5%

Total assets$1.2B+23.1%

Cash flow

See full

Operating cash flow-$167.4M-88.4%

CapEx$3.8M—

Free cash flow-$171.3M-92.7%

Valuation

See full

Market cap$11.66B+64.2%

Enterprise value$11.81B+67.5%

P/S10.3×-12.1×

Profitability

See full

Gross margin96.5%—

Operating margin-27.7%-12.2pp

Net margin-27.3%-12.0pp

FCF margin-59.8%-29.6pp

Returns & leverage

See full

Return on equity-49.3%-0.8pp

Debt / equity0.7×+0.5×

Current ratio3.5×-2.4×

Where this comes from

Reported directly by Madrigal Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized.

The official record: Madrigal Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Madrigal Pharmaceuticals, Inc.'s unrecognized compensation cost related to non-vested awards.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Madrigal Pharmaceuticals, Inc.'s unrecognized compensation cost related to non-vested awards?: Madrigal Pharmaceuticals, Inc. (MDGL) reported unrecognized compensation cost related to non-vested awards of $377.1M in Q1 2026.
How has Madrigal Pharmaceuticals, Inc.'s unrecognized compensation cost related to non-vested awards changed year-over-year?: Madrigal Pharmaceuticals, Inc.'s unrecognized compensation cost related to non-vested awards increased by 55.4% year-over-year, from $242.7M to $377.1M.